GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mural Oncology plc
Mural Oncology, a spinoff from Alkermes, is focused on developing next-generation immuno-oncology drugs. Its price trajectory will be determined by the results of clinical trials and investor confidence in the potential of its scientific developments.
Share prices of companies in the market segment - Cancer cure
Mural Oncology is a biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. We've categorized it as a Cancer Treatment company, and the chart below shows how investors value companies working on this promising class of oncology drugs.
Broad Market Index - GURU.Markets
Mural Oncology is an oncology company developing cytokine-based cancer treatments. As a component of the GURU.Markets index, it represents the immuno-oncology sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MURA - Daily change in the company's share price Mural Oncology plc
For Mural Oncology plc, an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
Mural Oncology plc is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with MURA's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Mural Oncology is a biotech company developing cancer treatments. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mural Oncology plc
Mural Oncology plc's year-to-date performance tells the story of its focus on developing antibody-drug conjugates (ADCs) for cancer treatment. Its 12-month market cap is entirely dependent on progress in clinical trials. As a spinoff from Alkermes, its primary objective is to prove the value of its lead candidate and scientific platform.
Annual dynamics of market capitalization of the market segment - Cancer cure
Mural, a private biotech company, is developing immunotherapy for cancer treatment. Its growth depends on success in clinical trials. Its valuation dynamics reflect investors' confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mural Oncology is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mural Oncology plc
Mural Oncology is an oncology company. Its monthly performance is typical for biotech companies: it depends entirely on progress in its scientific research and clinical programs. News of trial results or funding raises are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Mural Oncology is likely an Alkermes spinoff focused on oncology. The oncology sector is the largest and most dynamic in the pharmaceutical industry. The chart below shows general investor sentiment toward biotech companies developing new cancer treatments and their sensitivity to clinical trial data.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mural Oncology is an oncology company focused on developing specific treatments. Like other clinical-stage biotechs, its stock price will depend entirely on trial results, not overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mural Oncology plc
Mural Oncology, spun off from Alkermes, is a pure-play oncology company. Early weekly stock performance will be driven entirely by news of its lead drug's clinical trials and general sentiment in the biotech sector, which is creating high volatility.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Mural Oncology, a spinoff from Alkermes, is a pure-play oncology company. Early weekly stock performance will be driven entirely by news of its lead drug's clinical trials and general sentiment in the biotech sector, which is creating high volatility.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Mural, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing them to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
MURA - Market capitalization of the company Mural Oncology plc
The market capitalization chart of Mural Oncology, a spinoff of Alkermes, tells a focused story about the development of a new generation of immuno-oncology drugs. Its performance since the spinoff reflects investors' faith in its core asset—a cytokine that could become a breakthrough in cancer treatment.
MURA - Share of the company's market capitalization Mural Oncology plc within the market segment - Cancer cure
Mural Oncology is a clinical-stage oncology company focused on developing cytokine-based therapeutics. Its share of its segment's market capitalization reflects the potential of its scientific platform. The chart below shows the valuation volatility typical for biotech companies, dependent on clinical trial progress.
Market capitalization of the market segment - Cancer cure
Mural Oncology is a biopharmaceutical company focused on developing cytokine-based cancer treatments. The chart below shows the overall market capitalization of the oncology sector. It reflects the scientific interest in immunotherapy and efforts to develop more effective and safer ways to activate the immune system against tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows new hope in immuno-oncology. Mural Oncology was spun out of Alkermes to develop cytokine-based cancer therapy. Its line on the chart reflects investors' faith in this promising, yet highly competitive, treatment approach, as well as in the team leading it.
Book value capitalization of the company, segment and market as a whole
MURA - Book value capitalization of the company Mural Oncology plc
Mural Oncology's book value is its financial reserves and the rights to develop nemvaleukin alfa, a cytokine immunotherapy for cancer treatment. This represents focused scientific capital. The chart shows how this company, spun off from Alkermes, manages its budget to advance its key asset through late-stage clinical trials.
MURA - Share of the company's book capitalization Mural Oncology plc within the market segment - Cancer cure
Mural Oncology is a biotech company focused on developing cytokine cancer therapies. Its assets are comprised of intellectual property. The chart shows a minimal share of physical assets, typical for a company in clinical development.
Market segment balance sheet capitalization - Cancer cure
Immuno-oncology, as the BCap_Ges biotech chart shows, is a knowledge-intensive industry. Mural Oncology operates in this environment, where capital is invested in clinical research, not manufacturing. Its assets are intellectual property, not physical infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Mural Oncology's book value is the capital and intellectual property focused on developing oncology drugs. It reflects the financial foundation that will enable the company to conduct clinical trials and, ultimately, create new tangible drugs to fight cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mural Oncology plc
Mural Oncology is an oncology company. Like other biotechs, it thrives on research and development. Its market capitalization is a valuation of its future drug pipeline. Book value is secondary. The MvsBCap chart will reflect progress in clinical trials, which is the be-all and end-all for valuing such companies.
Market to book capitalization ratio in a market segment - Cancer cure
Mural Oncology is a biopharmaceutical company focused on developing oncology drugs. Its value depends on the success of its clinical programs. The chart reflects investor expectations regarding the future of its pipeline of drug candidates.
Market to book capitalization ratio for the market as a whole
Mural Oncology is a biotech company focused on developing immuno-oncology drugs. Its valuation depends almost entirely on the success of its R&D program. For such companies, book value means little. The chart illustrates how investors are betting on a scientific breakthrough in one of the most competitive fields of medicine.
Debts of the company, segment and market as a whole
MURA - Company debts Mural Oncology plc
Mural Oncology, a biotech company focused on developing a new class of immunotherapeutic drugs, relies entirely on external funding to conduct its clinical trials. This chart reflects the company's financial status during the R&D phase, when all resources are focused on science in the hopes of creating a breakthrough cancer treatment.
Market segment debts - Cancer cure
Mural Oncology is a biotech company focused on developing oncology drugs. Like any clinical-stage company, it relies entirely on external capital to fund its research. This chart provides insight into its financial structure and how it plans to bring its developments to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mural Oncology plc
Mural Oncology, like many biotech companies, is focused on developing cancer drugs. This chart shows its critical dependence on external funding to conduct expensive clinical trials. High debt is a bet on a future breakthrough, and a research failure could make it impossible to finance.
Market segment debt to market segment book capitalization - Cancer cure
Mural Oncology is an oncology company focused on developing cytokine-based cancer treatments. This chart shows the company's leverage in the immuno-oncology sector. It helps understand how the company finances its clinical programs in its quest to develop more effective and safe treatments, and how its strategy compares to its competitors.
Debt to book value of all companies in the market
Mural Oncology is a clinical-stage biopharmaceutical company focused on developing cytokine-based therapies for cancer treatment. The overall level of debt in the economy, reflected in this chart, shapes the investment climate. For a company conducting expensive research, access to capital is a key requirement for advancing its development.
P/E of the company, segment and market as a whole
P/E - Mural Oncology plc
For Mural Oncology, a biopharmaceutical company, this chart reflects investors' faith in its oncology developments. Its valuation is based on the potential of its drugs in clinical trials, not current profits, which is typical in the biotech sector, where risks and potential rewards are very high.
P/E of the market segment - Cancer cure
This chart shows the average price-to-earnings ratio for the biotech sector where Mural Oncology is developing. The industry's very high valuation reflects hopes for breakthroughs in cancer treatment. This metric provides a backdrop against which investors evaluate the scientific potential and risks associated with Mural's oncology portfolio.
P/E of the market as a whole
Mural Oncology is a biopharmaceutical company spun off from Alkermes, focused on developing cytokine-based immunotherapies for cancer treatment. This chart shows risk appetite in the biotech industry. It helps understand how investors view the prospects of this highly specialized approach to oncology and what expectations they have for the company following its spinoff.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mural Oncology plc
Mural Oncology is an oncology company focused on developing drugs targeting a growth factor that plays a key role in many types of cancer. Its future depends on the success of clinical trials. This chart reflects analysts' expectations regarding the potential of its lead drug candidate to become a new standard in targeted therapy.
%20P%2FE%20Mural%20Oncology%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mural-Oncology-plc&v=1772659691386 "Chart of the company's future (projected) P/E Mural Oncology plc")
Future (projected) P/E of the market segment - Cancer cure
Mural Oncology, a spinoff from Alkermes, is focused on developing cytokine-based immuno-oncology therapies for cancer treatment. This chart shows its future profitability expectations, allowing one to assess how highly the market values its specialized scientific approach and the potential of its lead candidates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772659691391 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Mural Oncology, a spinoff from Alkermes, is focused on developing cancer immunotherapy. As a new, highly specialized biotech company, it relies entirely on investors' faith in its science. This chart, showing the overall investment climate, serves as a barometer for Mural's availability of capital for conducting expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772659691413 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mural Oncology plc
Mural Oncology plc is a biotechnology company focused on developing cytokine-based therapies for cancer treatment. Its financial activity is driven by investments in clinical research. This chart illustrates the capital burn required to bring to market a new class of drugs that can stimulate the immune system to fight tumors.
Profit of companies in the market segment - Cancer cure
Mural Oncology is a biopharmaceutical company focused on developing cytokine therapies for cancer treatment. Their approach aims to stimulate the immune system without severe side effects. This graph reflects the high potential in immuno-oncology, where finding the "perfect" way to activate the immune system is a key goal for many companies.
Overall market profit
Mural Oncology is a biotech company focused on developing oncology drugs. Like the entire sector, access to funding for lengthy and expensive clinical trials is critical. This chart, reflecting market conditions, influences investor risk appetite.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mural Oncology plc
Mural Oncology is a biopharmaceutical company specializing in the development of a new class of oncology drugs targeting specific mutations in cancer cells. This chart reflects analyst expectations regarding the commercial potential of its targeted therapies, which depends on the results of clinical trials.
%20profit%20of%20the%20company%20Mural%20Oncology%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mural-Oncology-plc&v=1772659691500 "Graph of future (projected) profit of the company Mural Oncology plc")
Future (predicted) profit of companies in the market segment - Cancer cure
Mural Oncology is a biotech company focused on developing cytokine-based immunotherapeutics for cancer treatment. Its goal is to create potent yet safe drugs that stimulate the immune system. This chart shows profitability projections for the biotech sector, reflecting interest in new approaches in immuno-oncology that go beyond existing therapies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772659691513 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Mural Oncology is a biotech company focused on developing cancer treatments. Its value and ability to fund research depend on the biotech market sentiment. This chart, reflecting overall profit expectations, forms a macroeconomic backdrop that influences investor willingness to invest in high-risk assets.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772659691564 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mural Oncology plc
Mural Oncology is a biotech company specializing in cancer treatment. For a company in clinical development, this chart is a measure of investor faith in its scientific approach. Market value reflects the potential value of its future drugs, not current sales.
P/S market segment - Cancer cure
Mural Oncology plc is a biopharmaceutical company specializing in the development of cytokine-based immuno-oncology drugs. This chart shows the average revenue estimate in the biotech sector. It helps understand how highly investors value the potential revenue from Mural's innovative approach to using cytokines to stimulate the immune system against cancer.
P/S of the market as a whole
Mural Oncology, a spinoff from Alkermes, is focused on developing cytokine immunotherapies for cancer treatment. Their lead drug is designed to stimulate the anti-tumor immune response. This chart provides a general revenue metric against which to judge how highly investors value the new generation of oncology drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mural Oncology plc
Mural Oncology, a spinoff from Alkermes, is focused on developing a novel cytokine for cancer treatment. This chart reflects investor expectations for its lead drug candidate. The valuation is entirely dependent on the success of its clinical trials and its potential to become a key component of future immuno-oncology therapies.
%20P%2FS%20Mural%20Oncology%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mural-Oncology-plc&v=1772659691733 "The graph of the company's future (projected) P/S Mural Oncology plc")
Future (projected) P/S of the market segment - Cancer cure
Mural Oncology is a clinical-stage biopharmaceutical company focused on developing cytokine immunotherapies for cancer treatment. Its goal is to create potent yet safer drugs. This chart shows how the market evaluates its scientific approach compared to the competitive oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772659691844 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Mural Oncology is a biotech company focused on developing oncology drugs. Like many companies in this field, its value is based on expectations of future success. This graph, reflecting investors' overall risk appetite, directly impacts Mural's ability to raise capital. Market optimism is essential for funding long-term oncology research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772659691974 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mural Oncology plc
Mural Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. This chart reflects its financial flows, which at this stage likely come from research funding rather than commercial sales. It illustrates investments in developing new targeted therapies for cancer.
Sales of companies in the market segment - Cancer cure
Mural Oncology plc is a clinical-stage biopharmaceutical company focused on developing a new class of drugs known as antibody-cytokine conjugates for the treatment of cancer. Its activities are segmented into various development programs. This chart depicts the financial flows associated with one of its lead candidates, showing its progress.
Overall market sales
Mural Oncology plc is a biotechnology company focused on developing oncology drugs. Like other companies in this sector, its value is determined by its pipeline and progress in clinical trials. It works to solve complex medical problems, and its success depends not on short-term economic fluctuations, but on scientific breakthroughs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mural Oncology plc
Mural Oncology, a spinoff from Alkermes, focuses on developing cytokine immunotherapies for cancer treatment. Its future sales forecast is a market assessment of the potential of its lead drug candidate, which targets the immune system to fight tumors. This is a bet on a breakthrough in one of the most promising areas of oncology.
%20sales%20of%20the%20company%20Mural%20Oncology%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mural-Oncology-plc&v=1772659692094 "Schedule of future (projected) sales of the company Mural Oncology plc")
Future (projected) sales of companies in the market segment - Cancer cure
Mural Oncology is an oncology company focused on developing cancer treatments. This chart shows aggregate expectations for the entire oncology sector. It helps assess overall progress in developing new therapeutic methods, the level of investment in R&D, and the commercial potential analysts predict for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772659692101 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Mural Oncology, a biotech company focused on cancer treatment, depends on raising capital to finance lengthy and expensive clinical trials. This chart of overall sales forecasts reflects the overall market situation, which determines investor appetite for biotech investments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772659692107 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mural Oncology plc
Mural Oncology plc is a clinical-stage oncology company focused on developing cytokine-based therapies for the treatment of cancer. This chart reflects its financial position, with significant investments in research and development focused on developing a new class of anticancer drugs and achieving future profitability.
Market segment marginality - Cancer cure
Mural Oncology is a biopharmaceutical company focused on developing cancer treatments. Like many oncology startups, operational efficiency for them means advancing their research through costly clinical trials while using investor capital as efficiently as possible.
Market marginality as a whole
Mural Oncology plc is an oncology company focused on developing innovative cancer treatments. Its future depends on the success of clinical trials. This chart shows the profitability of mature businesses, while MURA's value lies in the potential of its scientific research to offer patients new, more effective treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Mural Oncology plc
Mural Oncology, a spinoff from Alkermes, is focused on developing a new class of immuno-oncology drugs. This chart shows its team of scientists and clinicians. The size of this team is an indicator of the investment in advancing its lead candidate, a cytokine therapy, through complex clinical trials.
Share of the company's employees Mural Oncology plc within the market segment - Cancer cure
Mural Oncology is a biotechnology company focused on developing immunotherapeutic drugs for the treatment of cancer. Its success depends entirely on the quality of its scientific team. This metric reflects its investment in human capital, which is key to the development of new anti-cancer drugs.
Number of employees in the market segment - Cancer cure
Mural Oncology is a biopharmaceutical company specializing in the development of cytokine-based cancer therapies. This chart reflects employment in the oncology sector. The growing number of scientists in the field of immuno-oncology reflects the search for new ways to stimulate the immune system to fight tumors, a core focus of Mural Oncology's research.
Number of employees in the market as a whole
Mural Oncology is a biopharmaceutical company, and its staff consists of highly qualified scientists. This graph reflects the general labor market, but for Mural and similar biotech companies, the key is scientific breakthroughs, which attract investment and allow them to expand their team of top specialists to fight cancer.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mural Oncology plc (MURA)
Mural Oncology plc is a biotech company focused on cancer treatment. Like many companies in this industry, it will have a very high market capitalization per employee. This chart shows that the company's entire value is derived from the market valuation of its scientific research and the potential for future drugs.
%20of%20the%20company%20Mural%20Oncology%20plc%20(MURA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mural-Oncology-plc-MURA&v=1772659692255 "Chart of market capitalization per employee (in thousands of dollars) of the company Mural Oncology plc (MURA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Mural Oncology plc is a clinical-stage biopharmaceutical company focused on developing immuno-oncology drugs. In this field, market capitalization per employee is a measure of investor perception of the clinical research potential and scientific potential. It is an indicator of the value of their development pipeline.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772659692283 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Mural Oncology plc is a biotech spinoff from Alkermes, focused on developing cytokine-based immunotherapies for cancer treatment. The chart illustrates how the market values its focused scientific team and its pipeline of promising oncology drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772659692293 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mural Oncology plc (MURA)
Mural Oncology is an oncology company spun out of Alkermes, focused on developing cytokine-based immunotherapies. It is a clinical-stage R&D company. This negative graph shows how much capital is burned per scientist working on this complex but potentially breakthrough cancer treatment technology, which requires significant investment before profitability.
%20Chart%20Mural%20Oncology%20plc%20(MURA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mural-Oncology-plc-MURA&v=1772659692308 "Company Profit Per Employee (in thousands of dollars) Chart Mural Oncology plc (MURA)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Mural Oncology is a biopharmaceutical company specializing in the development of cytokine-based drugs for the treatment of cancer. Their success depends on their scientific team conducting clinical trials. This metric reflects how effectively their investments in personnel lead to value creation and serves as a benchmark for comparison with other oncology startups.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772659692330 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Mural Oncology (MURA) is a biotech R&D company focused on oncology. Like others, it has no commercial products. This negative metric reflects the cost of maintaining a top-notch scientific team. It shows investors the extent of their investment in personnel working on developing future breakthrough drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772659692383 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mural Oncology plc (MURA)
Mural Oncology is an oncology company spun out of Alkermes, focused on developing a new class of immunotherapies. Currently in the clinical stage, it has no commercial revenue. This chart represents the future potential of its lead drug candidate.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mural-Oncology-plc-MURA&v=1772659692464 "Sales chart per company employee Mural Oncology plc (MURA)")
Sales per employee in the market segment - Cancer cure
Mural Oncology is an oncology company focused on developing cytokine-based therapies for cancer treatment. This chart compares revenue per employee (R&D) to the industry average. For a research-stage company, this reflects resource management efficiency and the value of their scientific portfolio to potential partners.
Sales per employee for the market as a whole
Mural Oncology (MURA) (an Alkermes spinoff) is a biotech company focused on developing cancer immunotherapy. Their lead candidate is a drug targeting interleukin-18. They are a clinical-stage R&D company with no commercial sales revenue. This graph would show $0, which is typical for a biotech company at this stage.
Short shares by company, segment and market as a whole
Shares shorted by company Mural Oncology plc (MURA)
Mural Oncology (MURA) is an oncology company spun out of Alkermes. Its success hinges on a single key cancer drug (nemvaleukin). The company's entire value is based on this drug. This chart shows the number of investors who doubt the drug's success or believe it won't compete with existing treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mural-Oncology-plc-MURA&v=1772659692617 "Short Shares Chart for the Company Mural Oncology plc (MURA)")
Shares shorted by market segment - Cancer cure
Mural Oncology is an oncology company spun out of Alkermes. They are focused on developing cytokine-based immunotherapies for cancer treatment. This chart shows the betting against the oncology biotech sector. It reflects the general pessimism of investors, who are betting that most drugs in this crowded sector will not prove effective.
Shares shorted by the overall market
Mural Oncology is a biotech focused on cancer treatment. It's a classic R&D story. This chart illustrates the general market "fear." When investors panic, they're unwilling to fund multi-year clinical trials. They see a company burning through cash and sell off shares, fearing they'll run out of cash before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mural Oncology plc (MURA)
Mural Oncology is a biotech company focused on developing cancer immunotherapy. Like many in its sector, the company's shares react sharply to news. This oscillator measures the strength of these reactions, helping identify when investor enthusiasm (above 70) or fear (below 30) reaches extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mural-Oncology-plc-MURA&v=1772659692742 "RSI 14 indicator chart for the company's stock Mural Oncology plc (MURA)")
RSI 14 Market Segment - Cancer cure
Mural Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies (antibody conjugates) for the treatment of cancer. This sector is highly dependent on clinical trial data. This chart shows the overall "temperature" in the volatile oncology biotech sector. It helps separate MURA's performance from the general "hype" or "disappointment" that has gripped the entire industry.
RSI 14 for the overall market
Mural Oncology (MURA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MURA (Mural Oncology plc)
Mural Oncology (spinned out of Alkermes) is a biotech company focused on developing an immuno-oncology drug (nemvaleukin) for the treatment of cancer. This chart shows the average target price. Analysts' forecasts are based on an assessment of nemvaleukin's clinical data and its potential in various combinations.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MURA-Mural-Oncology-plc&v=1772659692825 "A chart showing analyst consensus forecasts for the expected stock price. MURA (Mural Oncology plc)")
The difference between the consensus estimate and the actual stock price MURA (Mural Oncology plc)
Mural Oncology, a spinoff from Alkermes, focuses on developing next-generation immunotherapies (cytokines) for cancer treatment. This chart shows the difference between the market valuation and the consensus forecast. It highlights the potential experts see in their R&D portfolio and scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MURA-Mural-Oncology-plc&v=1772659692852 "A chart showing the difference between the consensus forecast and the actual stock price. MURA (Mural Oncology plc)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Mural Oncology is an oncology company spun out of Alkermes. It is focused on developing "conditioning" therapies (cytokines) to enhance CAR-T and cell therapies. This chart shows the overall analyst expectations for the oncology sector. It reflects whether experts believe this "adjuvant" therapy will be successful.
Analysts' consensus forecast for the overall market share price
Mural Oncology is a biotech company (spinned out of Alkermes) specializing in the development of "smart" immunotherapies (cytokines) that are activated only in tumors. This chart shows the overall market "risk appetite." For Mural, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mural Oncology plc
Mural Oncology is a biotech spinoff (spinned out of Alkermes) focused on engineered cytokines. Their R&D pipeline is aimed at creating improved versions of immune proteins for cancer treatment. This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Cancer cure
Mural Oncology (MURA) is an oncology company focused on developing targeted antibody-based therapies. Their goal is to create drugs (conjugates) for cancer patients with few treatment options. The chart shows the segment average. It helps investors assess how Mural's scientific potential and risks compare to the average in the drug development sector.
The AKIM Index for the overall market
Mural Oncology is an oncology company spun out of Alkermes. It develops new cytokine therapies (nemvaleukin) for cancer treatment. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this pure R&D company, focused on immuno-oncology, compares to overall economic trends.
